How much is Dilip Shanghvi Worth? Dilip Shanghvi Net Worth in 2026
Dilip Shanghvi’s net worth is estimated at $17 billion as of November 2026. Only about a quarter of that sits in his own name. The rest is inside Shanghvi Finance, a private holding company that owns 40.3 percent of Sun Pharma, and the arithmetic of how much of it is his is the main thing separating our figure from others.
| Net worth | $17 billion (estimate, range $11 billion to $24 billion) |
|---|---|
| Country | India |
| Known for | Founding and running Sun Pharmaceutical Industries |
| Main income sources | Sun Pharma shares held directly and through a family holding company, dividends |
| Direct holding | 9.60 percent of Sun Pharma, about 230 million shares |
| Latest event | Sun Pharma reported second-quarter results on October 30, 2026 |
How much is Dilip Shanghvi worth in 2026?
We estimate Dilip Shanghvi is worth about $17 billion, within a range of $11 billion to $24 billion. The company is listed, so share counts and prices are public. What is not public is how the family’s holding company is split among relatives, so this is a rough estimate at the edges.
Public estimates differ mostly on that split. Some count only his 9.6 percent. Some count the whole promoter group of 52.68 percent as if it were his. Neither is right: the first ignores the holding company he runs, the second ignores his family.
How Dilip Shanghvi built it
- Held shares through a family company. Shanghvi Finance owns 40.30 percent of Sun Pharma, beyond his direct 9.60 percent.
- Kept the promoters in control. The promoter group holds 52.68 percent of Sun Pharma as of September 2026.
- Kept buying growth. Sun Pharma's Organon acquisition was approved by Organon shareholders in 2026.
Learn the wealth mindset behind Dilip Shanghvi’s career in the Alux app.
Get the Alux appHow we got to $17 billion
We start from the price of Sun Pharma shares on October 30, 2026 (about 1,833 rupees) and the total of about 2.4 billion shares, which is his 230.4 million shares divided by 9.6 percent. That makes the company about $46 billion at about 95 rupees to the dollar, the October 30, 2026 close.
| Source | Our estimate | What it rests on |
|---|---|---|
| Shares in his own name | $4.4 billion | The shareholding pattern for September 2026 lists him at 9.60 percent of Sun Pharma, about 230 million shares. |
| Shanghvi Finance Private Limited | $14.9 billion | The same filing shows this company holds 40.30 percent, worth about $18.7 billion. We attribute 80 percent to him. That share is our assumption: his wife, children and one other family member hold 0.61 percent directly, and other relatives are not itemised. |
| Holding company discount | Minus $2.2 billion | Our assumption: 15 percent off the $14.9 billion, because a stake in an unlisted holding company cannot be sold at the screen price. |
| Total | $17.1 billion | $4.4 + $14.9 less $2.2 billion = $17.1 billion, which we round to $17 billion. |
We add nothing for other promoter entities (together about 2.2 percent of Sun Pharma), for property, or for stakes outside the company. The shareholding pattern shows almost none of the promoter shares pledged, so we make no adjustment for that.
Three quarters of the fortune is behind one door
Here is our calculation. After the discount, the holding company is worth $12.7 billion in our ledger. That is 74 percent of the unrounded $17.1 billion. His directly held shares, worth $4.4 billion, are the other 26 percent. A fortune that looks like a 9.6 percent stake is really a 40 percent one, held one level up.
The sensitivity is large. Each 1 percent move in the share price moves our figure by about $170 million, and each 10 points in the share we attribute to him moves it by about $1.6 billion (10 percent of $18.7 billion, less the 15 percent discount).
A profit that fell, a share price that rose
On October 30, 2026 Sun Pharma reported revenue of about 16,199 crore rupees, up 11.9 percent, and net profit of 1,989 crore rupees, down 36 percent because of a one-time loss of 1,269 crore rupees, according to The Hans India. The shares were trading about 4 percent higher at 1,833.30 rupees at midday. Kotak Neo reported that Organon shareholders approved Sun Pharma’s acquisition of the company, expected to close in early 2027 subject to approvals.
What would move the figure
The Organon closing is the next event in the record. The price Sun Pharma pays, and how it funds the purchase, will affect the share price that carries everything above. Any change to the family holding structure, or a share sale by the promoter group, would also replace our assumptions with filed numbers.
Dilip Shanghvi net worth FAQ
What is Dilip Shanghvi’s net worth?
Dilip Shanghvi’s net worth is estimated at $17 billion as of November 2026, in a range of $11 billion to $24 billion.
How much of Sun Pharma does Dilip Shanghvi own?
He holds 9.60 percent directly. A family holding company, Shanghvi Finance, holds another 40.30 percent, and the full promoter group holds 52.68 percent.
What is Sun Pharma worth?
About $46 billion at 1,833 rupees a share and 95 rupees to the dollar on 2.4 billion shares.
Did Sun Pharma make a profit in 2026?
Yes. The quarter to September 2026 showed net profit of 1,989 crore rupees, down 36 percent after a one-time loss of 1,269 crore rupees. The June quarter profit was 2,895 crore rupees.
What is Sun Pharma buying?
Organon. Its shareholders approved the deal and Sun Pharma expects it to close in early 2027.
How is Dilip Shanghvi’s net worth estimated?
We multiply Sun Pharma’s share count by its price, take his direct 9.6 percent and 80 percent of the family holding company’s 40.3 percent, then subtract a 15 percent discount on the holding company.
Related profiles
How we estimate net worth
Our estimates are based on public reporting, company valuations, and deal and earnings figures all compiled in an internal valuation model. They are approximate, and figures change over time as new information emerges.
Last updated: November 2026.